摘要
目的:探讨CD151在血管内皮生长因子A(vascular endothelial growth factor A,VEGFA)和血管内皮细胞生长因子受体(vascular endothelial growth factor receptor,VEGFR)阳性肺腺癌患者中的临床价值。方法:选取116例肺腺癌患者术后组织标本,应用免疫组织化学法检测VEGFA、VEGFR1、VEGFR2以及CD151蛋白的表达情况;分析CD151表达与VEGFA或VEGFR阳性肺腺癌患者临床特征之间的关系及对VEGFA或VEGFR阳性肺腺癌患者无病生存期(disease-free survival,DFS)的影响。结果:肺腺癌患者中VEGFA、VEGFR1、VEGFR2和CD151的阳性表达率分别为69.83%(81/116)、69.83%(81/116)、44.83%(52/116)和42.24%(49/116)。对于VEGFA阳性的肺腺癌患者,CD151蛋白阳性表达与TNM分期(r=0.24,P=0.04)和淋巴结转移(r=0.26,P=0.02)呈正相关;CD151是VEGFA阳性肺腺癌患者DFS的独立影响因子[风险比(hazard ratio,HR)=1.80,95%可信区间(condence interval,CI):1.00~3.19,P=0.048],CD151阳性表达患者的中位DFS(20个月)短于阴性表达患者(34个月,P<0.05)。对于VEGFR1阳性的肺腺癌患者,CD151蛋白阳性表达与TNM分期(r=0.28,P=0.01)和淋巴结转移(r=0.31,P<0.01)呈正相关。CD151也是VEGFR2阳性肺腺癌患者DFS的独立影响因子(HR=2.10,95%CI:1.02~4.33,P=0.044),CD151阳性表达患者的中位DFS(21个月)短于阴性表达患者(42个月,P<0.05)。结论:CD151是VEGFA和VEGFR2阳性肺腺癌患者DFS的独立影响因素。
Objective： To evaluate the clinical indications of CD151 in patients with lung adenocarcinoma with positive expressions of vascular endothelial growth factor A （VEGFA） or vascular endothelial growth factor receptor （VEGFR） Methods： The expressions of VEGFA, VEGFR1, VEGFR2 and CD151 in 116 specimens of patients with lung adenocarcinoma after surgery were detected by immunohistochemistry. The association of CD151 expression with the clinical features of patients with lung adenocarcinoma with positive expression of VEGFA or VEGFR was analyzed. The effect of CD151 expression on the disease-free survival （DFS） of patients with lung adenocarcinoma with positive expression of VEGFA or VEGFR was evaluated. Results： The positive rates of VEGFA, VEGFR1, VEGFR2 and CD151 in lung adenocarcinoma tissues were 69.83% （81/116）, 69.83% （81/116）, 44.83% （52/116）, and 42.24% （49/116）, respectively. For patients with lung adenocarcinoma with positive expression of VEGFA, positive expression of CD151 was positively correlated with clinical TNM stage （r = 0.24, P = 0.04） as well as lymph node metastasis （r = 0.26, P =- 0.02）. CD151 was an independent factor predicting DFS of patients with lung adenocarcinoma with positive expression of VEGFA [hazard ratio （HR） = 1.80, 95% confidence interval （C/）： 1.00 - 3.1 9, P = 0.048]. The median DFS of CD151-positive patients with positive expression of VEGFA was significantly shorter than that of CD151-negative patients （20 vs 34 months, P 〈 0.05）. For patients with lung adenocarcinoma with positive expression of VEGFR1, positive expression of CD151 was positively correlated with TNM stage （r = 0.28, P = 0.01） and lymph node metastasis （r = 0.31, P 〈 0.01）. Moreover, CD151 was an independent factor predicting DFS of patients with lung adenocarcinoma with positive expression ofVEGFR2 （HR = 2.10, 95%C/： 1.02 - 4.33, P = 0.044）, and the median DFS of CD151-positive patients with positive expression of VEGFR2 was significantly shorter than that of CD151-negative patients （21 vs 42 months, P 〈 0.05）. Conclusion： CD151 is an independent factor predicting DFS of patients with lung adenocarcinoma with positive expression of VEGFA or VEGFR2.
出处
《肿瘤》
CAS
CSCD
北大核心
2017年第10期1069-1078,共10页
Tumor
基金
天津市科技计划项目(编号:12ZCDZSY15600)~~
关键词
肺肿瘤
血管内皮生长因子A
血管内皮生长因子受体1
血管内皮生长因子受体2
抗原
CD151
无病生存
Lung neoplasms
growth factor receptor-I
Vascul Disease-free survival Vascular endothelial growth ar endothelial growth factor factor A： Vascular endothelia receptor-2
Antigen, CD151
